At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
Duloxetine +1 moredrug
Likely dose
Duloxetine 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder.
In Brief
A Phase 4 clinical trial evaluating Duloxetine and Placebo for Binge Eating and Depression. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this research study is to test the safety of duloxetine and see what effects (good and bad) it has on the subject's binge eating disorder and comorbid depressive disorder (depression occurring with binge eating disorder) compared to placebo (inactive pill).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBinge Eating, Depression
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedFeb 2008
Primary CompletionOct 2009
TodayJul 2026
First PostedFeb 6, 2008
Enrollment StartOct 1, 2006
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.4 years ago
Interventions
Duloxetinedrug
30 mg/day - 120 mg/day
Placebodrug
identical to study drug